Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis

Wahid, Braira

doi:10.1002/jmv.25557

Cited by 7 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is another study that reported the abrupt onset of diabetes and poor glycemic control following the DAA drug treatment. The evidence of the DAA drug induced hepatotoxicity is also available in the literature [16,17,18]. This case series also confirmed that the combination of sofosbuvir and ribavirin is not too effective due to which most of the clinicians in Pakistan prescribe sofosbuvir, ribavirin, and daclatasvir combination to the HCV patients.…”

Section: Discussionsupporting

confidence: 63%

Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series

et al. 2020

Self Cite

View full text Add to dashboard Cite

Hepatitis-C virus (HCV) is an enveloped RNA virus that currently infects more than 180 million people, worldwide. Interferon therapy was previously used as a standard therapy for HCV. Now it has been replaced with an interferon-free therapy or the direct acting antiviral (DAA) drug therapy. Although the DAA drug therapy is a potent strategy which has an excellent efficacy against the HCV infection with a majority of patients achieving sustained virological response (SVR), we report here three patients who experienced relapse after a 6-month long DAA drug therapy. The patients experienced relapse after receiving sofosbuvir (400mg) and ribavirin for 6 months. All three patients were later successfully treated with sofosbuvir, ribavirin, and daclatasvir combination. The current study highlights that the retreatment combination of sofosbuvir, ribavirin, and daclatasvir is more efficacious in the Pakistani population where practitioners are still using sofosbuvir and ribavirin.

show abstract

Section: Discussionsupporting

confidence: 63%

Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…AMES toxicity and hepatotoxicity are absent from almost all of the selected terpenes ( Table 4 ), except for DTXSID501019279, which demonstrates AMES toxicity and 3-cinnamyl-4-oxoretinoic acid, which exhibits hepatoxicity. The predicted toxicity of these two terpenes may not be disqualifying for their therapeutic use, since both tested drugs also fail at least one of these tests: dasabuvir also presents AMES toxicity, and several reports describe the hepatotoxicity of sofosbuvir [ 32 , 33 , 34 ]. The hepatotoxicity of dasabuvir was also described in a patient with kidney transplantation [ 35 ].…”

Section: Resultsmentioning

confidence: 99%

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking

et al. 2023

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a dangerous virus that is responsible for a large number of infections and deaths worldwide. In the treatment of HCV, it is important that the drugs are effective and do not have additional hepatotoxic effects. The aim of this study was to test the in silico activity of 1893 terpenes against the HCV NS5B polymerase (PDB-ID: 3FQK). Two drugs, sofosbuvir and dasabuvir, were used as controls. The GOLD software (CCDC) and InstaDock were used for docking. By using the results obtained from PLP.Fitness (GOLD), pKi, and binding free energy (InstaDock), nine terpenes were finally selected based on their scores. The drug-likeness properties were calculated using Lipinski’s rule of five. The ADMET values were studied using SwissADME and pkCSM servers. Ultimately, it was shown that nine terpenes have better docking results than sofosbuvir and dasabuvir. These were gniditrin, mulberrofuran G, cochlearine A, ingenol dibenzoate, mulberrofuran G, isogemichalcone C, pawhuskin B, 3-cinnamyl-4-oxoretinoic acid, DTXSID501019279, and mezerein. Each docked complex was submitted to 150 ns-long molecular dynamics simulations to ascertain the binding stability. The results show that mulberrofuran G, cochlearine A, and both stereoisomers of pawhuskin B form very stable interactions with the active site region where the reaction product should form and are, therefore, good candidates for use as effective competitive inhibitors. The other compounds identified in the docking screen either afford extremely weak (or even hardly any) binding (such as ingenol dibenzoate, gniditrin, and mezerein) or must first undergo preliminary movements in the active site before attaining their stable binding conformations, in a process which may take from 60 to 80 ns (for DTXSID501019279, 3-cinnamyl-4-oxoretinoic acid or isogemichalcone C).

show abstract

“…В результате данные о влиянии уровня вирусной нагрузки ВГС в настоящее время противоречивы и, как правило, пока не считаются значимыми предикторами токсического повреждения печени у пациентов с туберкулезом [9]. Несмотря на то, что до настоящего времени в литературе не сообщалось о гепатотоксичности, вызванной противовирусными препаратами прямого действия (ПППД), в одном из недавно опубликованных исследований был описан необычный случай вирусологического прорыва и повышения гепатотоксичности во время лечения препаратами ПППД у пациента, который ранее успешно лечился от туберкулеза [10].…”

Section:  обсуждениеunclassified

Viral Hepatitis C in Patients with Tuberculosis of the Respiratory System

Юпатов¹,

Дмитраченко²,

Кучко³

2022

Клиническая Инфектология И Паразитология

View full text Add to dashboard Cite

Целью исследования явилась оценка риска гепатотоксичности и активности вирусного гепатита С при проведении противотуберкулезной терапии у пациентов с коинфекцией ТБ/ГС.Исследование включало 43 пациентов с коинфекцией ТБ/ГС и 48 пациентов с ТБ. Результаты исследования не выявили повышенного риска гепатотоксичности противотуберкулезной терапии у пациентов с коинфекцией. Доля пациентов, у которых в процессе приема противотуберкулезных препаратов отсутствовало повышение биохимической активности либо эпизоды повышения печеночных ферментов и билирубина отмечались лишь однократно, была выше среди пациентов с коинфекцией ТБ/ГС (18,6% vs 8,3%) по сравнению с моноинфекций ТВ. В процессе проведения противотуберкулезной терапии также имелась тенденция к снижению вирусной активности ВГС у большинства пациентов с коинфекцией.У пациентов с коинфекцией по сравнению с моноинфекцией значительно чаще имела место множественная или широкая лекарственная устойчивость M. tuberculosis к противотуберкулезным лекарственным средствам (79,1% vs 41,67%). При этом показано отсутствие роста вирусной активности ВГС и отсутствие увеличения гепатотоксического влияния бедаквилина в составе комбинированной терапии при коинфекции ТВ/ГС. This study assessed the risk of hepatotoxicity and activity of viral hepatitis C during antituberculosis (antiTB) therapy in patients coinfected with tuberculosis and chronic viral hepatitis C (TB/CHC). Among the 91 examined patients, 43 had TB/CHC, and 48 had TB only. In the case of TB/CHC patients, antiTB therapy did not pose an increased risk of hepatotoxicity. The proportion of patients showing no increase in biochemical activity due to the intake of antiTB drugs or exhibiting only single episodes of elevated liver enzyme and bilirubin levels was higher for the TB/CHC group (18.6%) than for the TB group (8.3%). During antiTB therapy, a decrease in hepatitis C virus (HCV) activity was observed for most TB/CHC patients. Multiple or extensive resistance of M. tuberculosis to antiTB drugs was significantly more common in TB/CHC patients (79.1%) than in TB patients (41.67%). Notably, no increase in HCV activity or the hepatotoxic effect of bedaquiline as a part of the combination therapy for TB/CHC was observed.

show abstract

Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis

Cited by 7 publications

References 9 publications

Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series

Successful retreatment of HCV relapse patient with 4 weeks long sofsobuvir, ribavirin, and daclatasvir combination: Case Series

Discovery of Terpenes as Novel HCV NS5B Polymerase Inhibitors via Molecular Docking

Viral Hepatitis C in Patients with Tuberculosis of the Respiratory System

Contact Info

Product

Resources

About